The U.S. Food and Drug Administration (FDA) has approved Novocure’s Optune Pax, a type of Tumor Treating Fields (TTFields)…
Andrea Lobo
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘…
PANCREATIC CANCER
Oncolytics to test immunotherapy against aggressive pancreatic cancer
Oncolytics Biotech has cleared a significant hurdle in the U.S. to advance its unique viral immunotherapy, pelareorep, to a…
Thermo Fisher Scientific has received U.S. Food and Drug Administration (FDA) clearance for its EXENT System, an automated test that…
One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in…
A third dose of CER-1236, Cero Therapeutics’ T-cell therapy candidate for acute myeloid leukemia (AML), was administered to an…
GYNECOLOGICAL CANCER
New drug for endometrial cancer wins FDA’s breakthrough status
The U.S. Food and Drug Administration (FDA) has awarded breakthrough therapy status to rinatabart sesutecan (Rina-S), an investigational treatment for…
PANCREATIC CANCER
Daraxonrasib granted breakthrough designation for pancreatic cancer
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with…
GYNECOLOGICAL CANCER
CAR-T cell therapy for ovarian cancer enters next phase of testing
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian…